Abstract: As the third therapy following reconstructive surgery and organ transplantation, the therapy of regenerative medicine has been currently expected. The objective of regenerative medical therapy is to induce regeneration and repairing of defective and injured tissues based on the natural-healing potential of patients themselves. For successful tissue regeneration, it is undoubtedly indispensable to create a local environment that enables cells to efficiently proliferate and differentiate, resulting in the natural induction of tissue regeneration. Tissue engineering is a biomedical technology or methodology to build up this regeneration environment. For example, the technology of drug delivery system (DDS) enhances the biological functions of growth factors and the related genes for promoted tissue regeneration. This paper overviews the recent status of tissue regeneration based on the technology of growth factor release to emphasize significance of DDS technology in regenerative medical therapy.
Need for tissue engineering in regenerative medical therapy

Fundamental technology and methodology of tissue engineering
Considering the components consisting body tissue, there are three key factors; such as cells, the natural scaffold for cell proliferation and differentiation, and biosignaling molecules (growth factors and genes). There are four important technologies or methodologies for tissue engineering. The first technology is to prepare an artificial scaffold of cells proliferation and differentiation for tissue regeneration. It is well known that the extracellular matrix (ECM) is not only a physical support of cells but also provides a natural environment for cell proliferation and differentiation or morphogenesis which contributes to tissue regeneration and organogenesis 1) . is required to promote tissue regeneration, the direct injection of growth factor in solution into the site to be regenerated is generally not effective. This is because the growth factor is rapidly diffused from the injected site and is enzymatically digested or deactivated.
To enable the growth factor to efficiently exert its biological function, a technology or methodology is required. This is the drug delivery system (DDS), the second key technology of tissue engineering ( Fig. 1 ). Among the DDS technologies, the controlled release of growth factor at the site of action over an extended period is achieved by incorporating the factor into an appropriate carrier which is very important for tissue engineering. It is also highly possible that the growth factor is protected against its proteolysis, as far as it is, at least, incorporated in the release carrier, for prolonged retention of the activity in vivo. The release carrier should be degraded in the body since it is not needed after the growth factor release is completed. Other than the controlled release of drug, the objectives of DDS include the prolongation of drug half-life, the improvement of drug absorption, and drug targeting. For example, it is a promising approach to promote tissue regeneration by targeting a growth factor with a prolonged half-life to the tissue site to be regenerated. 
Successful tissue engineering by conttrolled release technology
We have succeeded in inducing the regeneration of various tissues and organs by the controlled release of various growth factors with the biological activities remaining as shown in Table   1 . This hydrogel system permits the controlled release of plasmid DNAs. The controlled release technology enabled a plasmid DNA and small interference RNA (siRNA) to enhance the level of gene expression and prolong the time period of gene expression [6] [7] . In addition, the hydrogel system can release not only one type of growth factor, but also two or multi-types of growth factor at the same time or in a time-order fashion. Upon applying a hydrogel incorporating low doses of either bFGF or TGF-β1 to a bone defect of rabbit skulls, no bone was regenerated at the defect. However, a synergistic effect on bone regeneration and angiogenesis was observed by the simultaneous release of two factors 10) . (Table. 1 ).
There are two important objectives of angiogenesis in tissue engineering, the therapy of ischemic disease and in advance angiogenesis for cell transplantation. As the former example, when injected into the ischemic site of myocardial infarction 13) or leg ischemia 14) , gelatin microspheres incorporating bFGF induced angiogenesis in a level that is therapeutically acceptable (Fig. 2 ).
This angiogenic therapy for leg ischemia has been permitted by angiogenesis efficiently improved the biological functions of pancreatic islets 15) , cardiomyocytes 16) , and kidney cells HairLength (mm)
induced by mesenchymal stem cells of bone marrow 18) . For the grafting surgery of heart, the bilateral sternum artery is normally used because of the high potency. However, in spite of successful graft surgery, the sternum repairing is often delayed, much worse the infection at the resection area of sternum often takes place, while wound healing of the surrounding soft tissue is also poor due to surgical elimination of their nutrient artery. As one trial to tackle the issue, we have applied the bFGF release system to this surgical therapy because bFGF has an inherent potential to induce bone regeneration as well as angiogenesis. A hydrogel sheet incorporating bFGF was applied to the soft tissue around the sternum of diabetic rats of which sternum was cut and the bilateral arteries were ligated. As expected, bone regeneration at the cut line of sternum was achieved together with enhanced angiogenesis and the recovery of blood flow at the surrounding soft tissue 19) .
This bFGF-induced simultaneous regeneration of bone and the surrounding blood vessels was also observed in a clinical study.
De novo adipogenesis was succeeded by the preadipocytes isolated from human fat tissues, gelatin microspheres incorporating bFGF, and a collagen sponge of cell scaffold 20) . Appropriate combination of all the three materials are needed to induce this adipogenesis.
We have found that a plasmid DNA could be released from a biodegradable hydrogel of cationized gelatin derivative to enhance the level of gene expression as well as prolong the time period 
Tissue engineering of internal medicine based on DDS technology
Presently, there is no effective therapy for chronic fibrosis diseases, such as lung fibrosis, cirrhosis, dilated cardiomyopathy, and chronic nephritis. For these diseases, the injured site of tissue and organ is normally occupied with fibrous tissue of excessive collagen fibers and fibroblasts. It is highly possible that this tissue ingrowth occupation causes impairment of natural healing process at the disease site. Therefore, if the fibrosis can be digested by any method to loosen or disappear, it is highly expected that the disease site is repaired based on the natural regeneration potential of the surrounding healthy tissue. It has been demonstrated that the injection of virus encoding a matrix metaloprotease (MMP) enzyme suppresses the tissue fibrosis to promote healing 22) . The finding strongly suggests that when collagen in the fibrous tissue is enzymatically digested, fibrosis is naturally improved or repaired due to the body potential to induce tissue regeneration which is naturally equipped in the surrounding healthy tissue. It is a new direction of tissue engineering that is called this regeneration therapy for chronic fibrosis diseases based on the natural potential of regeneration induction. This is defined as tissue engineering of internal medicine (Fig. 3) , because disease therapy induced by tissue regeneration potential is achieved by the drug treatment of internal medicine. We have demonstrated that the controlled release of a MMP-1 plasmid DNA at the medulla of chronic renal sclerosis induced the histological regeneration of kidney structure, in contrast to the plasmid DNA solution 23) . When gelatin microspheres incorporating hepatocyte growth factor (HGF) was intraperitoneally injected into rats with liver cirrhosis, the liver fibrosis was histologically cured 24) . However, the injection of HGF solution was not effective at all and the tissue appearance was similar to that of un-treated controlled group.
Necessity of tissue engineering technology in future regeneration therapy
Without using precursor and stem cells with high proliferation and differentiation potentials, presently, it has been possible to As tissue engineering is still in its infancy, it will take a long time to become well established although a part of the research projects has already come close to the stage of clinical applications.
Increasing significance of drug delivery in future will further help progress of tissue engineering. We will be happy if this short review stimulates readers' interest in the idea and research field of tissue engineering to assist understanding of the importance of release technology in tissue engineering. Fig. 3 The Concept of surgical tissue engineering and physical tissue engineering of internal medicine.
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